Reported Earlier, Nexalin Technology Raises $5.25M Via Public Offering Of 3M Shares At $1.75/Share

6/28/24 3:23:51 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $NXL alert in real time by email

Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))))) (the "Company" or "Nexalin") today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $5,250,000.

Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on July 1, 2024, subject to customary closing conditions.

Get the next $NXL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NXL

Date	Price Target	Rating	Analyst

More analyst ratings

Nexalin Technology CEO Provides Letter to Shareholders
HOUSTON, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") today released a letter to shareholders from its CEO Mark White: Dear Shareholders, I am pleased to provide an update on Nexalin Technologies' recent milestones, which underscore our commitment to advancing our patented Deep Intracranial Frequency Stimulation (DIFS) technology for the treatment of neurological and mental health conditions. The past months have brought exciting developments, particularly in our Alzheimer's research, showcasing Nexalin's dedication to offering non-invasive treatments without the potential side effects of medication. Alzheimer's R
11/11/24 8:00:00 AM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin's solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limi
11/1/24 2:00:00 PM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). "Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need," said Mark White, CEO of Nexalin. "This achievement not only underscores our commitment to driving shareholder value but also strength
11/1/24 10:34:54 AM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T
11/1/24 9:00:00 AM ET
$LOBO
$NXL
Motor Vehicles
Consumer Discretionary
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate
10/25/24 9:00:00 AM ET
$CLDI
$NXL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th
7/26/24 9:55:00 AM ET
$LOBO
$NXL
Motor Vehicles
Consumer Discretionary
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$NXL
Leadership Updates

Live Leadership Updates

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, ensuring Nexalin's commitment to innovation, safety, and excellence as the Company prepares to pursue global regulatory clearances and future FDA Breakthrough Device designations for its
10/14/24 8:30:00 AM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
‘Breaking Barriers' Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced that it has been selected to serve as a founding member of Breaking Barriers to Substance Use Recovery, a coalition of major industry participants and preeminent healthcare providers. Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Subst
7/18/24 8:30:00 AM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition ("Coalition"). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry. The Coalition is dedicated to advancing research, raising public awareness, and supporting clinical trials that address traumatic brain injuries, which affect millions each year. By joining the Coalition, Nexalin America underscores
5/22/24 8:30:00 AM ET
$NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Reported Earlier, Nexalin Technology Raises $5.25M Via Public Offering Of 3M Shares At $1.75/Share

Chat with this insight

Recent Analyst Ratings for
$NXL

$NXL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Chief Medical Officer Owens David bought $950 worth of shares (1,000 units at $0.95), increasing direct ownership by 0.68% to 147,793 units (SEC Form 4)

Chief Medical Officer Owens David bought $1,750 worth of shares (1,000 units at $1.75), increasing direct ownership by 0.69% to 146,793 units (SEC Form 4)

$NXL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Owens David bought $1,095 worth of shares (500 units at $2.19), increasing direct ownership by 0.34% to 148,293 units (SEC Form 4)

Amendment: Large owner Elson Marilyn was granted 700,000 shares, increasing direct ownership by 84% to 1,535,244 units (SEC Form 4)

Director Bernhard Leslie was granted 49,838 shares (SEC Form 4)

$NXL
SEC Filings

SEC Form 10-Q filed by Nexalin Technology Inc.

Nexalin Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NXL
Press Releases

Fastest customizable press release news feed in the world

$NXL
Financials

Live finance-specific insights

Nexalin Technology CEO Provides Letter to Shareholders

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

$NXL
Leadership Updates

Live Leadership Updates

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

$NXL
Market Insights

Live Market Insights

EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In June — Where Do Nvidia, GameStop, Tesla, Apple Rank?

Nexalin Technology shares are trading lower after the company announced the pricing of a $5.25 million public offering of 3 million shares at $1.75 per share.